Loading…
Company remains on track for Phase 1b/2 study data release in H1 2027.
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) announced it will present additional data from the Phase 1a single ascending dose trial of its TH103 drug candidate for neovascular age-related macular degeneration at the American Society of Retina Specialists (ASRS) Annual Meeting. The company also confirmed it is on schedule to share initial data from the Phase 1b/2 study in the first half of 2027.
The Phase 1a trial evaluated the safety, tolerability, and pharmacokinetics of TH103. Kalaris Therapeutics has a free float of 4,020,179 shares and 23,792,278 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.